Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?

References

• Grumelli C, Verderio C, Pozzi D, et al. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology 2005;26:761-7
   PubMed Web of Science ®Google Scholar
• Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20:783-91
   PubMed Web of Science ®Google Scholar
• Tsai CP, Chiu MC, Yen DJ, et al. Quantitative assessment of efficacy of dysport (botulinum toxin type A) in the treatment of idiopathic blepharospasm and hemifacial spasm. Acta Neurol Taiwan 2005;14:61-8
   PubMedGoogle Scholar
• Hsiung GY, Das SK, Ranawaya R, et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002;17:1288-93
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-65
   PubMed Web of Science ®Google Scholar
• Felber ES. Botulinum toxin in primary care medicine. J Am Osteopath Assoc 2006;106:609-14
   PubMedGoogle Scholar
• Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005;27:176-84
   PubMed Web of Science ®Google Scholar
• Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003;44:165-74
   PubMed Web of Science ®Google Scholar
• Gui D, Rossi S, Runfola M, et al. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Ther 2003;18:1-16
   PubMed Web of Science ®Google Scholar
• Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin Cutan Med Surg 2001;20:71-84
   PubMed Web of Science ®Google Scholar
• McLellan K, Das RE, Ekong TA, et al. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon 1996;34:975-85
   PubMed Web of Science ®Google Scholar
• Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 2005;20:937-44
   PubMed Web of Science ®Google Scholar
• Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993;86:493-4
   PubMed Web of Science ®Google Scholar
• Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004;19(Suppl 8):S129-36
   PubMed Web of Science ®Google Scholar
• Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med 1994;87:719
   PubMed Web of Science ®Google Scholar
• Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet 1994;344:474-5
   PubMed Web of Science ®Google Scholar
• Pearce LB, Borodic GE, First ER, et al. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128:69-77
   PubMed Web of Science ®Google Scholar
• Van den Bergh PY, Lison DF. Dose standardization of botulinum toxin. Adv Neurol 1998;78:231-5
   PubMedGoogle Scholar
• Sesardic D, Leung T, Gaines Das R, . Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals 2003;31:265-76
   PubMed Web of Science ®Google Scholar
• Wohlfarth K, Goschel H, Frevert J, et al. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 1997;355:335-40
   PubMed Web of Science ®Google Scholar
• Bigalke H. Botulinumtoxine: Wirksamkeit und Antigenizitaet. Klin Neurophysiol 2001;32:210-12
   Web of Science ®Google Scholar
• Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001;39:1815-20
   PubMed Web of Science ®Google Scholar
• Aoki K. Preclinical update on Botox (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol 1999;6(Suppl 4):3-10
   Web of Science ®Google Scholar
• Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006; 13( Suppl 1):2-10
   PubMed Web of Science ®Google Scholar
• Poulain B, Popoff MR, Molgó J. How do the Botulinum Neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 2008; 1:14-87
   Google Scholar
• Friday D, Bigalke H, Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Naunyn Schmiedebergs Arch Pharmacol 2002; 365(Suppl 2)
   Google Scholar
• Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-93
   PubMed Web of Science ®Google Scholar
• Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56:80-99
   PubMedGoogle Scholar
• Eisele K-H, Taylor HV. Dissociation of the 900 kDa neurotoxin complex for C. botulinum under physiological conditions. Toxicon 2008;51:28
   Google Scholar
• Wohlfarth K, Schwandt I, Wegner F, et al. Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 2008;255:1932-9
   PubMed Web of Science ®Google Scholar
• Wohlfarth K, Muller C, Sassin I, et al. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 2007;30:86-94
   PubMed Web of Science ®Google Scholar
• Sloop RR, Escutin RO, Matus JA, et al. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology 1996;46:1382-6
   PubMed Web of Science ®Google Scholar
• Kreyden OP, Scheidegger EP. Anatomy of the sweat glands, pharmacology of botulinum toxin, and distinctive syndromes associated with hyperhidrosis. Clin Dermatol 2004;22:40-4
   PubMed Web of Science ®Google Scholar
• Kranz G, Haubenberger D, Voller B, et al. Respective potencies of Botox(R) and Dysport(R) in a human skin model: a randomized, double-blind study. Mov Disord 2009;24:231-6
   PubMed Web of Science ®Google Scholar
• Hexsel D, Dal'Forno T, Hexsel C, et al. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg 2008;34:52-9
   PubMed Web of Science ®Google Scholar
• Rystedt A, Swartling C, Naver H. Anhidrotic effect of intradermal injections of botulinum toxin: a comparison of different products and concentrations. Acta Derm Venereol 2008;88:229-33
   PubMed Web of Science ®Google Scholar
• Karsai S, Adrian R, Hammes S, et al. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol 2007;143:1447-9
   PubMed Web of Science ®Google Scholar
• Trindade de Almeida AR, Marques E, de Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007;33 (1 Spec No.):S37-43
   PubMed Web of Science ®Google Scholar
• Rystedt A, Swartling C, Farnstrand C, et al. Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis. Acta Derm Venereol 2008;88:458-61
   PubMed Web of Science ®Google Scholar
• Clarke M, Oxman AD, eds. Cochrane Reviewers’ Handbook 4.1.5 [updated April 2002]. Oxford: Update Software. Updated quarterly, 2002.
   Google Scholar
• Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12
   PubMed Web of Science ®Google Scholar
• Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-62
   PubMed Web of Science ®Google Scholar
• Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997;235:197-9
   PubMed Web of Science ®Google Scholar
• Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A – Dysport and Botox – assuming a ratio of 4:1. Mov Disord 1997;12:1013-18
   PubMed Web of Science ®Google Scholar
• Poewe W. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:430
   PubMed Web of Science ®Google Scholar
• Talarico-Filho S, Mendonca DONM, Sperandeo DEMF, C DESP. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 2007;33 (1 Spec No.):S44-50
   PubMed Web of Science ®Google Scholar
• Simonetta Moreau M, Cauhepe C, Magues JP, et al. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003;149: 1041-5
   PubMed Web of Science ®Google Scholar
• Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 2006;55:975-80
   PubMed Web of Science ®Google Scholar
• Rzany B, Nast A. Head-to-head studies of botulinum toxin A in aesthetic medicine: which evidence is good enough?. J Am Acad Dermatol 2007;56:1066-7
   PubMed Web of Science ®Google Scholar
• Kollewe K, Buhr N, Krampfl K, et al. Long-term follow-up of cervical dystonia patients treated with Botulinum toxin A. Parkinsonism Relat Disord 2008;13(Suppl 2): Abstract 1.254
   Google Scholar